Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Neoplasms 15Endometrial Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Rectal Neoplasms 4Ovarian Neoplasms 4Head and Neck Neoplasms 4Pancreatic Neoplasms 3Melanoma 3Colonic Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Osteosarcoma 2Locally Advanced Rectal Cancer (LARC) 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Carcinoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1

Interventions

pembrolizumab 25Cisplatin 23Carboplatin 18Magnetic Resonance Spectroscopy 16Paclitaxel 15Specimen Handling 14Pemetrexed 11durvalumab 9Radiotherapy, Intensity-Modulated 8Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Nivolumab 7Radiation 6Docetaxel 6Cetuximab 6Biopsy 6osimertinib 5cemiplimab 5Taxes 5Radiotherapy 5Ipilimumab 5Cyclophosphamide 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5poly ICLC 4cabozantinib 4atezolizumab 4Oxaliplatin 4Gemcitabine 4Fluorouracil 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × dostarlimab × 1 year × Clear all
NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

University of Alabama at Birmingham

Phase 1/2 Recruiting
37 enrolled
Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

NCT06317311 2025-07-25

RUBY-J

GlaxoSmithKline

Phase 2 Active not recruiting
41 enrolled
Gynecologic

Carcinoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡